Last updated: 11/07/2018 19:35:26
Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets
Trial description: Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Patient self-described and physician-diagnosed sinus headache is predominately migraine and responds to open-treatment with sumatriptan. Curtis P. Schreiber, Susan Hutchinson Connie Powers Chris Webster Mary S. Richardson 55th Annual Meeting of the American Academy of Neurology 3/29/2003 Honolulu, HI; USA
Schreiber CP, Hutchinson S, Webster C, Ames M, et al. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed sinus" headache. Arch Intern Med 2004;164:1769-1772."
Sinussymptoms with migraine are consistent over multiple attacks. Schreiber, C. P., Hutchinson, S., Richardson, M. S., and Webster, C. J. 45th Annual Scientific Meeting of the American Headache Society (AHS) 6/19/2003 Chicago, IL; USA
Sumatriptan 50 mg consistently relieves migraine with sinussymptoms over multiple attacks. Hutchinson, S., Schreiber, C. P., Richardson, M. S., and Webster, C. J. 45th Annual Scientific Meeting of the American Headache Society (AHS) 6/19/2003 Chicago, IL; USA
Medical condition
Migraine Disorders
Product
sumatriptan
Collaborators
Not applicable
Study date(s)
October 2001 to June 2002
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2002-14-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website